Faculty

Back to Index
Alan L Epstein, MD, PhD
Professor of Pathology
Pathology
HMR 205 Health Sciences Campus Los Angeles
+1 323 442 1172

Overview

Alan L. Epstein MD, PhD is a Professor at the Keck School of Medicine at the University of Southern California and has over 30 years of experience in the laboratory developing monoclonal antibodies and other reagents for the treatment of cancer. He has published over 150 papers in the field and has filed 25 patents including those describing the use of TNT antibodies for the imaging and therapy of cancer. Along with TNT antibodies, Dr. Epstein has invented the Lym-1 antibody for the treatment of lymphoma, vasopermeability enhancing antibodies to increase the uptake of drugs and antibodies in tumors, the LN panel of diagnostic antibodies, and most recently several novel fusion proteins for the immunotherapy of cancer. He has been a consultant for numerous biotechnology companies and is an accomplished speaker and scientist in his field. Dr. Epstein holds a bachelor’s degree in biology from Wesleyan University, Middletown, CT and obtained the MD and PhD degrees from the Medical Scientist Training Program at Stanford University School of Medicine. Before coming to the University of Southern California, Dr. Epstein started his academic career in the Department of Medicine, Division of Medical Oncology at the Northwestern University School of Medicine in Chicago.

Publications

Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling. Sci Rep. 2017 Jan 03; 7:39751. View in: PubMed

Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice. Autoimmunity. 2016 Aug; 49(5):298-311. View in: PubMed

Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthet Surg J. 2016 Jul; 36(7):773-81. View in: PubMed

Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models. Cancer Immunol Immunother. 2016 May; 65(5):511-23. View in: PubMed

Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016 Mar; 26(3):381-9. View in: PubMed

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. J Immunol Res. 2016; 2016:2342187. View in: PubMed

Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant. J Immunother Cancer. 2016; 4:11. View in: PubMed

Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015 Mar; 135(3):695-705. View in: PubMed

Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia(®)) in Dogs with Spontaneous Malignancies. J Cancer Sci Ther. 2015; 7(6):167-174. View in: PubMed

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 1; 20(23):6034-44. View in: PubMed

Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. Expert Rev Anticancer Ther. 2014 Oct; 14(10):1243-9. View in: PubMed

BRAF(V600E) in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration. Thyroid. 2014 Sep; 24(9):1385-93. View in: PubMed

Boron neutron capture therapy as new treatment for clear cell sarcoma: Trial on different animal model. Appl Radiat Isot. 2014 Jun; 88:59-63. View in: PubMed

A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody. ACS Nano. 2014 Mar 25; 8(3):2064-76. View in: PubMed

CD8+ T Cell-Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma. J Immunol. 2014 Jan 1; 192(1):224-33. View in: PubMed

Cytoreductive Chemotherapy Improves the Biodistribution of Antibodies Directed against Tumor Necrosis in Murine Solid Tumor Models. Mol Cancer Ther. 2013 Dec; 12(12):2827-36. View in: PubMed

Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013 Nov-Dec; 36(9):477-89. View in: PubMed

Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur J Immunol. 2013 Sep; 43(9):2421-9. View in: PubMed

Generation of tumor-targeted antibody-CpG conjugates. J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. View in: PubMed

Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1. Urology. 2013 Feb; 81(2):464. e1-9. View in: PubMed

Survival Signals and Targets for Therapy in Breast Implant-Associated ALK- Anaplastic Large Cell Lymphoma. Clin Cancer Res. 2012 Sep 1; 18(17):4549-59. View in: PubMed

An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas. Clin Cancer Res. 2012 Sep 1; 18(17):4657-68. View in: PubMed

The perichromatin region of the plant cell nucleus is the area with the strongest co-localisation of snRNA and SR proteins. Planta. 2012 Aug; 236(2):715-26. View in: PubMed

Unique approach for B lymphoma therapy. Blood. 2012 Apr 19; 119(16):3647-8. View in: PubMed

A rare case of noninsulinoma pancreatogenous hypoglycemia syndrome. Case Rep Gastrointest Med. 2012; 2012:164305. View in: PubMed

Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators. J Clin Cell Immunol. 2012; Suppl 5:004. View in: PubMed

Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies. Appl Radiat Isot. 2011 Dec; 69(12):1713-6. View in: PubMed

Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy. 2011 Nov; 3(11):1317-40. View in: PubMed

USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics. Oral Oncol. 2011 Sep; 47(9):810-7. View in: PubMed

A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin Cancer Res. 2011 Apr 1; 17(7):1645-8. View in: PubMed

Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer. 2011 Apr 1; 117(7):1478-89. View in: PubMed

Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab. J Rheumatol. 2011 Feb; 38(2):398-9. View in: PubMed

Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011; 9:90. View in: PubMed

A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res. 2010 Nov 15; 70(22):9041-52. View in: PubMed

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010 Aug 15; 185(4):2273-84. View in: PubMed

Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol. 2010; 2:5. View in: PubMed

Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J Immunol. 2009 May 1; 182(9):5430-8. View in: PubMed

Influence of an educational seminar on use of disease activity measurements by rheumatologists in treatment of rheumatoid arthritis. J Rheumatol. 2009 Mar; 36(3):532-8. View in: PubMed

Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. Cancer Immunol Immunother. 2008 May; 57(5):677-84. View in: PubMed

Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother. 2008 Apr; 31(3):235-45. View in: PubMed

Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res. 2008 Jan 15; 14(2):579-88. View in: PubMed

Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res. 2007 Jul 1; 13(13):4016-25. View in: PubMed

Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. View in: PubMed

RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. View in: PubMed

Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res. 2007 May 1; 13(9):2758-67. View in: PubMed

Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. Leuk Lymphoma. 2007 May; 48(5):944-56. View in: PubMed

Soluble Fc fusion proteins for biomedical research. Methods Mol Biol. 2007; 378:33-52. View in: PubMed

B7. 1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. View in: PubMed

H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models. J Immunother. 2006 May-Jun; 29(3):274-83. View in: PubMed

131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm. 2006 Feb; 21(1):5-14. View in: PubMed

Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res. 2005 Dec 1; 11(23):8492-502. View in: PubMed

Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. View in: PubMed

NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. View in: PubMed

Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol. 2005 Mar 1; 23(7):1538-47. View in: PubMed

chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics. 2004 Feb; 23(1):1-10. View in: PubMed

Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G. J Leukoc Biol. 2004 Jan; 75(1):99-105. View in: PubMed

Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res. 2003 Dec 1; 63(23):8384-92. View in: PubMed

Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. View in: PubMed

Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003 Aug 15; 63(16):5046-53. View in: PubMed

Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics. 2003 Aug; 22(4):197-207. View in: PubMed

LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother. 2003 Jul-Aug; 26(4):320-31. View in: PubMed

Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood. 2003 Jun 15; 101(12):4853-61. View in: PubMed

Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. View in: PubMed

Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003 May 21; 95(10):741-9. View in: PubMed

Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid Hybridomics. 2003 Feb; 22(1):1-9. View in: PubMed

Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics. 2002 Dec; 21(6):421-32. View in: PubMed

Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm. 2002 Aug; 17(4):359-70. View in: PubMed

Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. Cancer Genet Cytogenet. 2002 May; 135(1):48-56. View in: PubMed

Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells. Hybrid Hybridomics. 2002 Feb; 21(1):11-8. View in: PubMed

Powered bySC CTSI